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Abstract
Background: Ampullary adenocarcinoma is considered to have a better prognosis than either pancre-
atic or bile duct adenocarcinoma. Pancreaticoduodenectomy is associated with significant mortality and
morbidity. Some recent publications have advocated the use of endoscopic papillectomy for the treat-
ment of early ampullary adenocarcinoma. This article reviews investigations and surgical treatment
options of ampullary tumours.
Methods: A systematic review of English-language articles was carried out using an electronic search of
the Ovid MEDLINE (from 1996 onwards), PubMed and Cochrane Database of Systematic Reviews
databases to identify studies related to the investigation and management of ampullary tumours.
Results: Distinguishing between ampullary adenoma and adenocarcinoma is challenging given the
inaccuracy of endoscopic biopsy, for which high false negative rates of 25–50% have been reported.
Endoscopic ultrasound is the most accurate method for local staging of ampullary lesions, but distin-
guishing between T1 and T2 adenocarcinomas is difficult. Lymph node metastasis occurs early in the
disease process; it is lowest for T1 tumours, but the risk is still high at 8–45%. Case reports of successful
endoscopic resection and transduodenal ampullectomy of T1 adenocarcinomas have been published,
but their duration of follow-up is limited.
Conclusions: Optimal staging should be used to distinguish between ampullary adenoma and adeno-
carcinoma. Pancreaticoduodenectomy remains the treatment of choice for all ampullary adenocarcinomas.
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Introduction
Ampullary malignancies are rare tumours with a reported inci-
dence of fewer than one case per 100 000 population.1 Although
these malignancies account for <5% of pancreatic and other
biliary malignancies, the rate of ampullary adenocarcinoma in
the USA increased annually from 1973 to 2005.1 The incidence
of ampullary malignancy increases with advancing age, most
notably after the age of 50 years; according to the Surveillance,
Epidemiology and End Results (SEER) database in the USA,
the median age at diagnosis is 65 years.1,2 It has been proposed
that ampullary adenocarcinoma develops from pre-cancerous
adenomas via an adenoma–carcinoma sequence, similar to that
seen in colorectal cancer.3–5 Significantly, up to 50% of ampullary
villous adenomas contain a focus of adenocarcinoma at the time
of diagnosis.6,7 Studying patients with familial adenomatous
polyposis (FAP) has provided some insight into the natural
history of ampullary adenoma. Duodenal adenomas occur in up
to 95% of FAP adults, with most occurring in the periampullary
region.8 The rate of progression to adenocarcinoma is very slow
and it is estimated that only 5% of ampullary adenomas progress
to adenocarcinoma.9
Because of their unique location, ampullary malignancies often
present early in the course of the disease with obstructive jaun-
dice.10 Early lymph node metastasis is common, but patient pres-
entation usually occurs prior to distant organ metastasis.11 In a
10-year study by Tien et al.,11 only eight (5%) of 163 patients with
ampullary adenocarcinoma had liver metastases at the time of
presentation. However, diagnosis at an advanced age renders many
patients unsuitable for surgery; data from the SEER database show
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that only 40% of patients diagnosed with ampullary adenocarci-
noma undergo resection.2
Given the advanced age of presentation with ampullary adeno-
carcinoma and the significant mortality and morbidity associated
with pancreaticoduodenectomy, recent attention has focused on
alternative methods of treatment.12 Case reports of the successful
treatment of ampullary adenocarcinomas by transduodenal
ampullectomy and endoscopic papillectomy (EP) have been pub-
lished.13,14 The aim of this review is to summarize the literature
regarding investigations into surgical treatment options for resect-
able ampullary malignancies.
Materials and methods
Evidence acquisition
Studies reporting on the investigations and treatment of ampul-
lary tumours were sought. Literature searches using Ovid
MEDLINE (from 1996), PubMed and the Cochrane Database of
Systematic Reviews databases were performed. Boolean logic
methods were used to combine medical subject heading (MeSH)
terms to identify the articles referenced in this paper. The full
strategy for the electronic search of the PubMed database is out-
lined in Appendix 1. One reviewer (JA) selected articles based on
titles and abstract content. In cases of doubt, articles were
reviewed in their entirety. Reference lists of relevant publications
were hand-searched for additional studies missed by the search
strategy. The last date on which a literature search was undertaken
was 4 August 2012.
Study inclusion criteria
The study methodology adhered to the PRISMA (preferred
reporting items for systematic reviews and meta-analyses) recom-
mendations for improving the standard of review articles.15 Only
studies published in the English language from January 2000
onwards were included. When multiple studies describing the
same patient population were identified, the most recent publica-
tion was used.
Studies on diagnostic tests were required to report at least one
of the following outcomes: sensitivity; specificity; positive and
negative predictive values, and tumour and node staging. Studies
describing clinical outcomes were required to report one or more
of the following: morbidity and mortality; time to recurrence, and
time to death.
Data extraction and quality control
The literature retrieval and screening of relevant studies was per-
formed by JA. The title and abstract of each article were appraised
and, if they gave any suggestion of providing relevant data, the full
text was retrieved.
Statistical analysis
Statistical analysis was not possible as the data could not be
pooled. The included studies displayed varied and specific areas of
interest (e.g. diagnostic tools, endoscopic intervention, surgery)
and not all modalities were available to all patients in each study.
There was significant heterogeneity in both study design and the
quality of the included studies.
Results
The initial search using the search strategy outlined earlier iden-
tified a total of 689 studies (Fig. 1). The titles and abstracts of the
selected studies were appraised. Full texts were retrieved for a total
of 213 articles, of which 104 were found to meet the inclusion
criteria for this review. The most common reason for exclusion
was reporting on ampullary adenomas but not adenocarcinomas.
In addition, studies that did not distinguish between ampullary
and periampullary adenocarcinomas in their data were excluded.
Investigations and clinical staging
The presence of an ampullary tumour can be confirmed using
different diagnostic modalities. Endoscopy, endoscopic ultra-
sound (EUS), abdominal US, computed tomography (CT),
magnetic resonance imaging (MRI) and positron emission tom-
ography (PET) can all be employed to help diagnose and stage
these tumours.13,16 The anatomical location of the ampulla and
small size of ampullary tumours renders the detection of a lesion
mass difficult, although indirect signs of bile and pancreatic duct
dilatation are easier to detect.17,18 Furthermore, distinguishing
between benign and malignant tumours is problematic given the
inaccuracy of the investigations.16,17,19 An abdominal US is inaccu-
rate at detecting ampullary tumours: reported detection rates
range from 12% to 27%.16,20,21 An elevated carbohydrate antigen
19-9 (CA 19-9) level may help to guide the diagnosis towards an
ampullary adenocarcinoma, although 37% of patients with
adenocarcinoma have been found to have normal CA 19-9
levels.10
Endoscopic characteristics can help differentiate between
benign and malignant tumours. Ampullary adenomas are typi-
cally discoloured lobular lesions, whereas firmness, ulceration and
Studies identified through
database search
n = 689 
Studies excluded after
screening titles and abstracts
n = 476 
Full-text articles retrieved and
assessed for eligibility
n = 213 
Studies included in review
n = 104
Figure 1 Modified PRISMA (preferred reporting items for system-
atic reviews and meta-analyses) flow diagram showing study
methodology
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duodenal wall adherence are present in malignancies with local
invasion.13 Narrowband imaging endoscopy may also help to diag-
nose ampullary malignancies, although diagnostic criteria have
yet to be established.22
Endoscopic biopsies of ampullary adenocarcinomas have poor
diagnostic accuracy; high false negative rates range between 25%
and 50%.19,23,24 Biopsy accuracy is also reported to decrease with
repeated biopsies.11 In addition, endoscopic biopsy often under-
estimates the actual pathology and an endoscopic diagnosis of
high-grade dysplasia is associated with an underlying adenocarci-
noma on definitive pathology in 50–100% of patients.25,26 Endo-
scopic US-guided biopsy can be used to help increase diagnostic
accuracy.27 In a small 35-patient study, EUS-guided biopsy dis-
played diagnostic accuracy close to 90% in assessing ampullary
tumours.27
Although up to 50% of ampullary villous adenomas contain a
focus of adenocarcinoma at the time of diagnosis, ampullary
tumour size has not been shown to be a factor in differentiating
between benign and malignant tumours.6,7,10 Winter et al.10
studied 450 patients with ampullary tumours and reported that
the median adenocarcinoma size (2.0 cm) was smaller than the
median adenoma size (2.9 cm). However, Tien et al.11 suggested
that tumour size is important in predicting malignancy and docu-
mented that 28% of adenocarcinomas but only 12% of adenomas
were >3.0 cm in size.
The use of 18-fluorodeoxyglucose (18-FDG) PET for detecting
periampullary neoplasms and for differentiating between benign
and malignant tumours has been studied.28–30 Sperti et al.28
described 11 of 14 ampullary tumours which showed 18-FDG
focal uptake, but found a high false positive rate as four of five
adenomas also showed focal uptake of the tracer. Similarly,
Wakabayashi et al.29 concluded that although PET was superior
to CT in diagnosing malignant disease in patients with biliary
strictures, false positive results were obtained in patients with
benign inflammatory conditions.
Accurate pretreatment staging of an ampullary malignancy is
important, especially given the suggestion that adenocarcinoma
confined to the mucosa can be treated endoscopically.31 Table 1
outlines the accuracy of CT in staging ampullary tumours. Tech-
nological advances in CT have resulted in enhanced image reso-
lution and detection rates have subsequently improved.16,20 In a
study by Skordilis et al.20 published in 2002, only four of 20 amp-
ullary tumours were detected using a 10-mm slice thickness in CT.
Artifon et al.32 used a 5-mm slice thickness and image reconstruc-
tion in a series in which all 27 ampullary tumours were detected.
However, despite these improvements, the accuracy of CT for
tumour (T) (26% or 52%) and node (N) (43–65%) staging
remains low (Table 1). Computed tomography more frequently
understages than overstages ampullary tumours; however, its use
in staging should be routine given its ability to detect distant
metastatic disease.32
Chen et al.21 have suggested that MRI and EUS are superior to
CT and conventional US for T- and N-staging. However, both
MRI and EUS are limited in their ability to distinguish between
early malignant adenocarcinoma and benign adenoma.21 Eight
studies, including those by Chen et al.21 and Kim et al.,33 which
reported on overall T- and N-staging accuracy, have reported
accuracies of MRI in identifying an ampullary tumour ranging
between 4% and 81% (Table 1).16,34–38
Of the diagnostic modalities, EUS represents that which has
been most studied; its overall accuracy in correctly diagnosing
T-stage is reported to range from 63% to 82% (Table 2). Accu-
racies reported for correct N-staging range from 60% to 81%
(Table 2). Critically, success in differentiating between T1 and T2
tumours is variable, as acknowledged by Ito et al.13 in their
review of this subject. The addition of intraductal US, or
Table 1 Accuracy of computed tomography and magnetic resonance imaging in staging ampullary tumours
Authors n Tumour detection Correct staging
n Sensitivity Specificity T-stage N-stage
Computed tomography
Skordilis et al. 200220 20 4 11/17
Maluf-Filho et al. 200465 10 30% 98% 7/10
Chang et al. 200717 24 24 92%a 92%a
Artifon et al. 200932 27 14/27 15/27
Chen et al. 200921 28 8 6/23 10/23
Tien et al. 200911 54 8 15% 100%
Lee et al. 201166 20 48% 86%
Magnetic resonance imaging
Kim et al. 200733 25 24 14/15
Chen et al. 200921 16 13 7/13 10/13
Chung et al. 201138 19 17 84% 86%
aSensitivity and specificity for tumours of >12.3 mm.
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contrast-enhanced harmonic imaging, to EUS may improve its
diagnostic accuracy.13,39,40
The role of staging laparoscopy has been questioned, given the
high resectability rate using pancreaticoduodenectomy in early
disease presentation without distant metastases.41,42 Vollmer
et al.42 showed that diagnostic laparoscopy and laparoscopic US
did not alter management in 22 patients with ampullary tumours.
Brooks et al.41 performed diagnostic laparoscopy in 67 patients
with ampullary tumours, in six (9%) of whom laparoscopy
detected distant metastases that had not been previously detected
by CT. Similarly, Tilleman et al.43 did not recommend staging
laparoscopy when they detected distant metastatic disease in 6%
of patients undergoing laparotomy for ampullary tumours, but
performed a palliative bypass in these patients.
Treatment of early ampullary adenocarcinoma and
lymph node metastasis
Pancreaticoduodenectomy, or a modification of it, is the mainstay
of surgical treatment for ampullary malignancies.10 Other surgical
procedures that have been employed include transduodenal
ampullectomy, pancreas-sparing segmental duodenectomy, pan-
creas head resection with segmental duodenectomy, and complete
resection of the extrahepatic portion of the common bile duct and
the ampulla.23,44,45
Benign ampullary adenomas have historically been treated sur-
gically until the 1990s when EP gained popularity. EP was
described in 1987 by van Stolk and with improved endoscopic
techniques and pre-operative investigations this has now become
the treatment of choice for most adenomas.46,47 Ampullary
tumours have been observed to spread along the mucosa of the
pancreatic and biliary ducts prior to any muscular invasion.48,49
This ductal extension has been noted in both benign and malig-
nant tumours and is a critical factor in the consideration of local
treatment options.48 Bohnacker et al.50 reported successful EP for
benign tumours with up to 1.0 cm of intraductal growth.
Given the success of endoscopic resection in the treatment of
benign ampullary adenoma, attention has turned to the role of EP
in early ampullary adenocarcinoma. For EP to be curative, accu-
rate tumour staging is essential and the risk for lymph node
metastasis must be considered.12 The risk for lymph node metas-
tasis significantly increases with tumour depth, degree of differ-
entiation and microvascular invasion.10 Other tumour-related
factors, including tumour size, an ulcerative morphology and
perineural invasion are also associated with an increased risk for
lymph node metastasis.10,51 Table 3 displays pooled data from
several studies addressing the risk for lymph node metastasis
based on individual tumour characteristics.10,12,23,31,48,52,53
The roles of local resection, EP and transduodenal ampullec-
tomy are controversial and attention has primarily focused on T1
disease, in which the risk for lymph node metastasis is lowest. As
Table 3 shows, there is a high risk for lymph node metastasis even
in the early stage of the disease process. Table 4 addresses this risk
specifically in T1 disease. In a series reported by the Johns
Hopkins Medical Institute, only 9% of surgically treated ampul-
lary adenocarcinomas were identified as T1 tumours.10 In addi-
tion, it is worth noting that over 50% of patients undergoing
pancreaticoduodenectomy for ampullary adenocarcinoma display
lymph node metastases.10,51 The posterior pancreaticoduodenal
lymph node group is the most commonly involved.54–56
Given the high risk for lymph node metastasis,Winter et al.10 and
Y-S Yoon et al.48 concluded that local resection should not be
considered as an alternative to pancreaticoduodenectomy. By con-
trast, SM Yoon et al.,31 Woo et al.12 and Ito et al.13 have suggested the
risk for lymph node metastasis is negligible provided strict criteria
are met. In a retrospective study by Woo et al.12 of 57 T1 tumours
treated by pancreaticoduodenectomy no lymph node metastases
were seen in well differentiated focal tumours less than 2 cm in size
which displayed no angiolymphatic invasion. Thirteen (6%)
patients met this criteria in their retrospective review of 216
Table 2 Accuracy of endoscopic ultrasound in staging ampullary tumours
Authors n Tumour
detected
Correct staging
T1 T2 Overall T N-stage
Skordilis et al. 200220 20 20 14/17 12/17
Maluf-Filho et al. 200465 10 9 5/8 6/10
Ito et al. 200767 40 38 13/21 5/11 25/40
Artifon et al. 200932 27 27 11/13 20/27 22/27
Chen et al. 200921 41 40 4/7 12/17 24/33 22/33
Imazu et al. 201039 4 4 0/1 3/4
Manta 201037 24 24 15/24
Table 3 Risk for lymph node metastasis based on primary tumour
characteristics
Primary tumour size T-stage Differentiation
<1.0 cm: 7–12% T1: 8–45% Good: 19–25%
1.0–2.0 cm: 26–57% T2: 23–51% Moderate: 39–42%
2.0–3.0 cm: 39–47% T3: 38–72% Poor: 44–53%
>3.0 cm: 33% T4: 57–78%
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patients with ampullary adenocarcinoma over a fifteen year
period.12 Endoscopic papillectomy has been used to treat T1 adeno-
carcinoma; published case reports and series are displayed in
Table 5. These data show that T1 adenocarcinoma has a very low
recurrence rate when treated with EP. However, these studies are
limited by small numbers of patients in each report and short-term
follow-up. The American Society for Gastrointestinal Endoscopy
guidelines, published in 2006, suggest that EP should not be per-
formed for ampullary adenocarcinoma.46 The information shown
in Table 5 does not give reason to change this recommendation.
Transduodenal ampullectomy can be performed with lower
morbidity and mortality than the more radical pancreaticoduo-
denectomy.11 This procedure should be considered for adenomas
that are not amenable to EP and in which preoperative biopsy
and thorough preoperative investigations do not suggest malig-
nancy. Tien et al.11 performed 20 transduodenal ampullectomies
on ‘benign’ lesions of <3.0 cm in size and utilized intraopera-
tive frozen-section biopsy to confirm the benign nature of the
lesion and to ensure clear bile and pancreatic duct margins. Final
histology confirmed adenocarcinoma in only two (10%) of
the lesions, both of which were subsequently treated with
pancreaticoduodenectomy.
The role of transduodenal ampullectomy in the treatment of
adenocarcinoma has been questioned because of the reported low
negative margin (R0) resection rate and high disease recurrence
rate.24 R0 resection rates as low as 40% and recurrence rates of up
to 100% are of concern.23,24,53,57,58 Significantly, these earlier studies
did not report T-staging. Subsequent studies have focused on
transduodenal ampullectomy in T1 adenocarcinomas (Table 6)
and have shown a low recurrence rate provided that an R0 resec-
tion can be achieved in patients without lymph node metastases.
Beger et al.23 performed 10 transduodenal ampullectomies with
local lymph node dissection and achieved longterm success in
four patients. However, all of the six patients in whom R1 resec-
tion was achieved had recurrent disease within 3 years. Signifi-
cantly, following transduodenal ampullectomy, disease recurrence
occurred locally and with distant liver metastases and was not
amenable to further surgery.59 Frozen-section biopsy at the time of
operation should be used to confirm clear resection margins and
lymph node status.14 Proceeding to a pancreaticoduodenectomy if
positive margins or malignant lymph nodes are present is recom-
mended.14 In patients with confirmed ampullary adenocarcinoma
Table 4 Lymph node metastasis in T1 ampullary adenocarcinoma
Authors Patients with
T1 disease, n
Patients with
lymph node
metastasis, n
Yoshida et al. 200068 9 0
Todoroki et al. 200369 9 1
de Castro et al. 200424 36 10
Yoon et al. 200548 67 6
Kobayashi et al. 200660 3 1
Lee et al. 200670 30 3 (17a)
Terasawa et al. 200671 15 3
Barauskas et al. 200772 4 0
Yoon et al. 200731 52 4
Bogoevski et al. 200873 7 0 (6b)
Winter et al. 200910 25 7
Woo et al. 200912 57 5
Hornick et al. 201174 11 5
Lee et al. 201155 10 2
aMicrolymphovascular invasion present in 17 patients.
bNodal microinvolvement present in six patients.
Table 5 Endoscopic papillectomy for T1 ampullary adenocarcinoma
Authors n Tumour Recurrence, n Follow-up, months
Park et al. 200075 1 T1 1 28
Jung et al. 200119 1 T1 0 2
Tokunga et al. 200276 1 Well differentiated 0 48
Ito et al. 200477 1 T1 mucosal 0 7
Neeves et al. 200678 1 T1 mucosal 0 24
Katsinelos et al. 200779 1 T1 mucosal 0 7
Well differentiated
Yoon et al. 200731 6 T1 mucosal 0 32 mean
Fukushima et al. 200980 1 T1 mucosal 0 6
Harano et al. 201081 2 T1 mucosal 0 17 and 172
Yamashita et al. 201082 1 T1 mucosal 0 23
Well differentiated
Ito et al. 201177a 12 T1 4/28 15–41
Salmi et al. 201183 2 T1 mucosal 0 42 mean
aThis study included an additional 16 patients with adenomas and did not differentiate between malignancy and adenoma; all recurrences were
successfully treated with argon plasma coagulation.
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who are deemed too frail to undergo pancreaticoduodenectomy,
ampullectomy may be considered, although the low R0 resection
rate and high risk for recurrence must be acknowledged.60
In a series reported by Park et al.,14 three of eight patients with
T1 adenocarcinoma displayed lymph node metastases at the time
of transduodenal ampullectomy and none survived longterm.
This outcome highlights not only the high rate of lymph node
metastasis in T1 disease, but also the difficulty of determining
preoperatively which patients have local disease only. Again,
studies addressing the role of transduodenal ampullectomy in T1
adenocarcinoma are limited by small patient samples.
Pancreaticoduodenectomy remains the treatment of choice in
ampullary adenocarcinoma and can achieve an R0 resection rate
of >95%.10 Improvements in surgical technique and perioperative
care have reduced morbidity and 30-day mortality subsequent to
this procedure.61 The largest published single-centre series of pan-
creaticoduodenectomies for ampullary adenoma and adenocarci-
noma (n = 435) reported postoperative mortality of 2% and
morbidity of 52% (Table 7).10
Prognosis
Ampullary adenocarcinoma is considered to have a better prog-
nosis than either pancreatic or bile duct adenocarcinoma, with
larger series reporting 5-year survival rates of 37–68%.10,12,24 This
can be partially explained by earlier diagnosis and the less frequent
occurrence of adverse pathological factors.62 There is still,
however, a high risk for disease relapse and the most important
prognostic indicators for recurrent disease are the presence of
lymph node metastasis and pancreatic invasion (T3).51 Lymph
node-positive disease is associated with median survival that is
less than a third of that in lymph node-negative disease (23
months versus 79 months).10 The number of positive nodes pre-
dicts survival. In a study by Sakata et al.,63 no patients with four or
more positive nodes survived 5 years. Pancreatic invasion is a poor
prognostic indicator. Berberat et al.64 reported a series in which no
patient with T3 or T4 disease survived 5 years.
Table 8 depicts prognosis following pancreaticoduodenectomy
for T1 ampullary adenocarcinoma. The largest study to address
this issue included 61 patients and reported 5-year survival of
83%, although it did not differentiate between node-negative and
node-positive disease.48 Any longterm results of alternative treat-
ment methods for T1 ampullary adenocarcinoma should be com-
pared against this standard.
Table 6 Transduodenal ampullectomy for T1 ampullary adenocarcinoma
Authors n Disease recurrence Follow-up, months
Beger et al. 199923 10 R0: 0/4 60 for three patients
R1: 6/6 36
Posner et al. 200084 2 0 61 and 11
Nikfarjam et al. 200185 4 0 20 median
Bohra et al. 200286 1 1 10
Fraguela Marina 200387 4 0 13 mean
Dixon et al. 200559 6 2 33 mean
Meneghetti et al. 200526 5 1 –
Genc et al. 200788 1 1 15
Park et al. 200714 8 N0: 0/5 46 mean
N1: 3/3 deceased
Shiba et al. 200989 1 0 10
Honda et al. 201090 2 0 1
Table 7 Morbidity and mortality in pancreaticoduodenectomy for
ampullary adenocarcinoma in studies with sample sizes of >50
Authors Patients, n Morbidity Mortality
Duffy et al. 200391 55 49% 0%
Todoroki et al. 200369 56 9% 0%
de Castro et al. 200424 120 52% 5%
Brown et al. 200592 51 47% 2%
Giorgio et al. 200593 64 34% 9%
Roggin et al. 200553 99 67% 5%
Yoon et al. 200548 201 34% 1%
Balachandran et al. 200694 113 48% 8%
Hsu et al. 200651 135 59% 3%
Qiao et al. 200795 124 40% 10%
Falconi et al. 200896 96 58% 4%
Yao et al. 200897 67 21% 0%
Berberat et al. 200964 75 37% 1%
Tien et al. 200911 64 39% 3%
Winter et al. 200910 435a 52% 2%
Yeh et al. 201098 147 49% 4%
Choi et al. 201199 68 45% 3%
Showalter et al. 2011100 61 8% –
aIncludes 90 pancreaticoduodenectomies for ampullary adenomas.
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Conclusions
Optimal staging should be used to distinguish between ampullary
adenoma and adenocarcinoma. Endoscopic biopsy has a high false
negative rate and EUS-guided biopsy provides a more accurate
assessment. Endoscopic US is superior to MRI and CT for local
staging. However, the accurate differentiation of T1 and T2
adenocarcinomas is difficult. Ampullary adenocarcinoma metas-
tasizes to local lymph nodes early in the course of the disease. This
risk is lowest in T1 tumours, but remains in the range of 8–45%.
T1 tumours represent <10% of ampullary adenocarcinomas in
Western populations. It has been proposed that local resection by
EP or transduodenal ampullectomy can be curative in selected T1
adenocarcinomas; however, the case series supporting this claim
are limited by small patient numbers and short follow-up periods.
Pancreaticoduodenectomy remains the treatment of choice for all
ampullary adenocarcinomas.
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Appendix 1 Search strategy: PubMed
01 Ampulla tumour
02 Ampullary tumour
03 #1 or #2 and imaging
04 #1 or #2 and computer tomography
05 #1 or #2 and magnetic resonance imaging
06 #1 or #2 and endoscopic ultrasound
07 #1 or #2 and ultrasound
08 #1 or #2 and positron emission tomography
09 #1 or #2 and laparoscopy
10 #1 or #2 and pancreaticoduodenectomy
11 #1 or #2 and endoscopic papillectomy
12 #1 or #2 and ampullectomy
13 #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #11 or #12
14 Filter: English
15 Filter: Human
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